Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure  by Spieker, Lukas E et al.
Acute Hemodynamic and
Neurohumoral Effects of Selective
ETA Receptor Blockade in
Patients With Congestive Heart Failure
Lukas E. Spieker, MD, Veselin Mitrovic, MD,* Georg Noll, MD, FESC, Richard Pacher, MD,†
Matthias R. Schulze, MD,‡ Jo¨rg Muntwyler, MD, MPH, Christoph Schalcher, MD,
Wolfgang Kiowski, MD, FACC, FESC, Thomas F. Lu¨scher, MD, FACC, FRCP, FESC, on behalf of the
ET 003 Investigators
Zurich, Switzerland; Bad Nauheim and Dresden, Germany; and Wien, Austria
OBJECTIVES To investigate the hemodynamic effects of the selective endothelin (ET)A receptor antagonist
LU135252 in patients with congestive heart failure (CHF).
BACKGROUND Nonselective ETA/B receptor antagonists improve hemodynamics in patients with CHF.
Since ETB receptors mediate the release of nitric oxide and the clearance of ET-1, selective
ETA antagonists are of special interest.
METHODS The hemodynamic effects of a single oral dose of the selective ETA receptor antagonist
LU135252 (1, 10, 30, 100 or 300 mg) were investigated in a multicenter study involving 95
patients with CHF (New York Heart Association II–III) with an ejection fraction #35%.
RESULTS Baseline ET-1 positively correlated with pulmonary vascular resistance, pulmonary capillary
wedge pressure (PCWP), and mean pulmonary artery pressure (MPAP, r 5 0.37–0.50, p ,
0.0004) but were inversely related to cardiac index (CI; r 5 20.36, p 5 0.0004). LU135252
dose dependently increased CI and decreased mean arterial pressure and systemic vascular
resistance (p , 0.03–0.0002), while heart rate remained constant or decreased slightly.
Pulmonary capillary wedge pressure, MPAP, pulmonary vascular resistance and right atrial
pressure also decreased significantly (p , 0.035–, 0.0001). Two hours after LU135252,
plasma ET-1 did not significantly increase after 1 mg but did so by 23% (p 5 0.003), 29%
(p 5 0.0018), 56% (p , 0.0001) and 101% (p , 0.0001) after 10, 30, 100 and 300 mg,
respectively, while plasma catecholamines remained constant.
CONCLUSIONS In patients with CHF, a single oral dose of the selective ETA receptor antagonist LU135252
improves hemodynamics in a dose-dependent manner without activation of other neurohu-
moral systems and is well tolerated over a wide dose range. (J Am Coll Cardiol 2000;35:
1745–52) © 2000 by the American College of Cardiology
The vascular endothelium produces and releases endothelin
(ET)-1, nitric oxide (NO) and prostacyclin and, thereby,
plays a fundamental role in the regulation of vascular tone
and structure (1–3). EndothelinA and ETB receptors medi-
ate the vasoconstrictor effects of ET-1 in smooth muscle
cells (4–6). Endothelin-1 also induces proliferation of
vascular smooth muscle cells and myocardial hypertrophy
(7–9). In contrast, endothelial ETB receptors cause vasodi-
lation via release of NO and prostacyclin, which also exert
antithrombotic and antiproliferative effects in vascular
smooth muscle cells (10–12). Further, ETB receptors in the
pulmonary circulation are important for the clearance of
ET-1 (13–16).
Increased peripheral resistance is a key feature of conges-
tive heart failure (CHF). Apart from activation of neuro-
hormonal systems—such as the sympathetic nervous system
(13) and the renin angiotensin system (14)—there is evi-
dence that increased ET-1 production contributes to vaso-
constriction as well. Indeed, plasma levels of ET-1 are
elevated, and plasma levels of the precursor of ET-1, big
ET-1, are strong, independent predictors of death in pa-
tients with heart failure (15–17). In experimental heart
failure of the rat, ETA receptor blockade improves survival
(18). In patients with CHF, nonselective ETA/B blockade
improves pulmonary and systemic hemodynamics (19,20).
Although there are good reasons to develop ET receptor
antagonists for the treatment of CHF, it remains contro-
versial whether nonselective ETA/B receptor antagonists or
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selective ETA receptor antagonists should be used. Since
ETB receptors stimulate the release of NO, which is
impaired in heart failure (21), and are also involved in the
pulmonary clearance of ET-1 (22–25), selective ETA recep-
tor antagonists are of particular interest. We investigated
the hemodynamic and neurohumoral effects of a single oral
dose of LU135252, a selective ETA endothelin receptor
antagonist, in patients with CHF.
METHODS
Patients. A total of 100 patients with CHF with an
ejection fraction #35% as assessed by echocardiography or
isotope ventriculography of any underlying cause (except
primary organic valvular heart disease) participated in a
prospective multicenter trial (for centers see Acknowledg-
ments). Each patient gave written, informed consent, and
this study was approved by the local ethical committees of
each of the participating centers.
Inclusion and exclusion criteria. The following baseline
criteria had to be met for inclusion: pulmonary capillary
wedge pressure (PCWP) $14 mm Hg or cardiac index (CI)
#2.8 l/min/m2. Exclusion criteria were acutely decompen-
sated heart failure (New York Heart Association IV),
sustained or symptomatic systemic hypotension (systolic
blood pressure #90 mm Hg), acute myocardial infarction
within three months before study enrollment, unstable
angina pectoris, primary valvular heart disease, continued
pacemaker rhythm, stroke within six months before study
enrollment, introduction of beta-adrenergic blocking agent
therapy within three months before study enrollment, preg-
nancy or lactation, liver disease, renal failure (creatinine
.220 mmol/l) and exposure to any investigational drug
during the last month before study entry.
Experimental protocol. Patients continued their usual
medications except on the investigational day. All drugs
with impact on hemodynamic parameters were discontinued
the morning of the study. Different open-label dosage levels
(1, 10, 30, 100 and 300 mg) were studied in different patient
groups.
After recording stable hemodynamic baseline values for
30 min, LU135252 was administered orally with 200 ml
water. Arterial blood pressure and hemodynamic variables
were measured at 30, 60, 90, 120, 180 and 240 min after
oral administration of the drug. Blood samples were drawn
from the atrial part of the Swan-Ganz catheter or a
peripheral vein shortly before the hemodynamic measure-
ments. Electrocardiographic monitoring was performed
throughout the entire investigational period. Four hours
after administration of LU135252, the Swan-Ganz catheter
was withdrawn. For safety reasons, the patients spent the
following night in the hospital.
Hemodynamic measurements. Cardiac output (average of
at least two measurements) was determined by thermodilu-
tion with a Swan-Ganz catheter inserted through a sheath
introducer system in a jugular or cubital vein and propagated
to the pulmonary artery. Right atrial pressure, systemic and
pulmonary artery pressure and PCWP were measured.
Cardiac index and systemic and pulmonary vascular resis-
tance were calculated using standard formula. Heart rate
was obtained from electrocardiogram monitoring.
Determination of plasma levels. Blood samples were
drawn at baseline and 30, 60, 90, 120, 180 and 240 min after
administration of LU135252. Plasma, obtained by centrif-
ugation, was stored at 270°C until analysis. Plasma levels of
ET-1 and catecholamines were assayed 15 min before and
120 and 240 min after administration of the study drug
using methodology described previously (26–28). Plasma
norepinephrine in healthy subjects averaged 208 6
75 pg/ml with the assay used. The concentration of ET-1 in
plasma from healthy control subjects with this assay was
2.8 6 0.5 pg/ml (27).
Statistical analysis. Means and proportion of baseline
characteristics were calculated overall and by treatment
assignment. The average mean change of the hemodynamic
variables at 120, 180 and 240 min according to treatment
assignment was estimated with repeated-measurement
analysis of covariance, adjusting for the respective baseline
values and assuming compound symmetry among the three
time categories (SAS PROC MIXED). For all hemody-
namic parameters, time and time*dose interaction was not
Abbreviations and Acronyms
CHF 5 congestive heart failure
CI 5 cardiac index
ET 5 endothelin
MPAP 5 mean pulmonary artery pressure
NO 5 nitric oxide
PCWP 5 pulmonary capillary wedge pressure
Table 1. Main Demographic and Hemodynamic Data of the
Study Patients (n 5 95)
Age (yrs) 56.9 6 10.6
Gender (male/female) 86/9
Weight (kg) 78.1 6 13.2
Height (m) 1.73 6 0.07
BMI (kgzm22) 26.1 6 3.6
Systolic blood pressure (mm Hg) 125 6 20
Diastolic blood pressure (mm Hg) 76 6 14
Heart rate (min21) 73 6 15
Cardiac index (mlzmin21zm22) 2.3 6 0.4
Systemic vascular resistance (dynzs21zcm25) 1,570 6 388
Right atrial pressure (mm Hg) 7 6 4
Mean pulmonary artery pressure (mm Hg) 30 6 12
Pulmonary capillary wedge pressure (mm Hg) 19 6 7
Pulmonary vascular resistance (dynzs21zcm25) 204 6 160
Values represent means 6 standard deviation.
BMI 5 body mass index.
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significant. For the estimated changes of the five treatment
doses, statistical significance was assumed at a Bonferroni-
adjusted p value of ,0.05/5 5 0.01. To test the dose-
response effect, dose was entered as an ordinal variable into
the model, and significance was defined as an alpha level of
,0.05.
RESULTS
Patients’ characteristics and medication. Five of the 100
patients entering the study were excluded because they did
not fulfill the hemodynamic inclusion criteria or because
they met one or more exclusion criteria. Baseline demo-
graphic and hemodynamic characteristics of the 95 study
patients are shown in Table 1. The concomitant cardiovas-
cular medication of the study patients is listed in Table 2.
Plasma endothelin and hemodynamics at baseline. Base-
line hemodynamics at baseline according to treatment group
are shown in Table 3. Baseline ET-1 averaged 2.7 6
0.1 pg/ml (range 1.3–7.9 pg/ml). Baseline ET-1 plasma
levels positively correlated with pulmonary vascular resis-
tance (r 5 0.50, p , 0.0001), PCWP (r 5 0.37, p 5 0.004),
mean pulmonary artery pressure (MPAP) (r 5 0.46, p ,
0.0001), systemic vascular resistance (r 5 0.21, p 5 0.051)
and right atrial pressure (r 5 0.22, p 5 0.03; Fig. 1). In
contrast, ET-1 levels were inversely related to CI (r 5
20.36, p 5 0.0004). Baseline ET-1 levels were not corre-
lated with heart rate nor with systemic mean arterial
pressure. The correlation between hemodynamic parameters
was not altered by exclusion of the single patient with a very
high ET plasma level and remained highly significant
(correlation between ET-1 plasma levels and MPAP, r 5
0.42, p , 0.0001; PCWP, r 5 0.34, p 5 0.001; CI, r 5
0.34, p 5 0.001).
Hemodynamic effects. ARTERIAL CIRCULATION. The he-
modynamic changes after administration of LU135252 are
shown in Table 4. LU135252 led to a dose-dependent
increase in CI. The average mean increases in CI after 1, 10,
30, 100 or 300 mg of LU135252, respectively, were 18%,
111% (both NS), 113% (p , 0.01), 119% (p , 0.01) and
22% (p , 0.01). Mean arterial pressure decreased by 5%,
5%, 3%, 5% and 10% (p , 0.01 for all dosages). Accord-
ingly, systemic vascular resistance decreased dose depen-
dently by 11% to 27% (p , 0.01 for all dosages except
1 mg). Importantly, heart rate remained stable. After 24 h,
LU135252 still reduced arterial blood pressure by 25%
(p 5 0.06), 26% (p 5 0.016), 0.1% (NS), 215% (p 5
0.008) and 210% (p 5 0.0016). The lack of a strict dose
dependency of the blood pressure lowering effect is ex-
plained by accidental, nonsignificant differences in the
baseline blood pressure between the dosage groups
(Table 3).
PULMONARY CIRCULATION. The changes in pulmonary he-
modynamics after administration of LU135252 are shown
in Table 4. Right atrial pressure was reduced by 12% to 19%
(p , 0.01 for 30 and 100 mg). Mean pulmonary artery
pressure decreased by 10% to 20% (p , 0.01 for all dosages
except 1 mg). Pulmonary capillary wedge pressure was
reduced by 15% to 25% (p , 0.01). Pulmonary vascular
resistance dose dependently decreased by 6% to 26% (p ,
0.01 for 100 and 300 mg).
Endothelin plasma levels after ETA blockade. Two hours
after LU135252, plasma ET-1 dose dependently increased
Table 2. Concomitant Cardiovascular Drugs of the
Study Patients
Angiotensin-converting enzyme inhibitor 93% (n 5 88)
Diuretic 86% (n 5 82)
Digoxin 68% (n 5 65)
Nitrate 53% (n 5 50)
Aspirin 42% (n 5 40)
Beta-blocker 39% (n 5 37)
Cordarone 28% (n 5 27)
Oral anticoagulant 27% (n 5 26)
Statin 16% (n 5 15)
Angiotensin II antagonist 12% (n 5 11)
Calcium antagonist 8% (n 5 8)
Fibrate 3% (n 5 3)
Table 3. Baseline Hemodynamic Parameters According to Treatment Group
LU135252 Dose
p Value1 mg 10 mg 30 mg 100 mg 300 mg
CI (l/min) 2.3 6 0.3 2.3 6 0.3 2.3 6 0.5 2.4 6 0.4 2.1 6 0.4 0.32
HR (beats/min) 72 6 16 72 6 15 73 6 19 77 6 12 70 6 14 0.72
MAP (mm Hg) 92 6 11 92 6 16 87 6 15 97 6 15 87 6 10 0.16
SVR (dynzs21zcm25) 1,637 6 343 1,632 6 409 1,423 6 401 1,621 6 379 1,558 6 393 0.36
RAP (mm Hg) 8.6 6 4.6 6.3 6 3.0 7.4 6 3.8 7.3 6 5.6 7.1 6 3.6 0.63
MPAP (mm Hg) 30 6 11 29 6 10 30 6 14 32 6 12 29 6 11 0.91
PCWP (mm Hg) 21 6 9 19 6 8 19 6 6 19 6 5 18 6 7 0.87
PVR (dynzs21zcm25) 183 6 91 166 6 85 208 6 205 247 6 207 205 6 140 0.58
Values represent means 6 SD.
CI 5 cardiac index; HR 5 heart rate; MAP 5 mean systemic arterial pressure; MPAP 5 mean pulmonary artery pressure; PCWP 5 pulmonary capillary wedge pressure;
PVR 5 pulmonary vascular resistance; RAP 5 right atrial pressure; SVR 5 systemic vascular resistance.
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by 6% after administration of 1 mg of the ETA antagonist
(p 5 0.47), by 23% after 10 mg (p 5 0.003), by 29% after
30 mg (p 5 0.002), by 56% after 100 mg (p , 0.0001) and
by 101% after 300 mg (p , 0.0001), respectively (Fig. 3).
Plasma catecholamines. Baseline plasma norepinephrine
levels averaged 531 6 78 ng/ml and baseline epinephrine
levels 56 6 6 ng/ml.
Baseline norepinephrine plasma levels positively corre-
lated with pulmonary vascular resistance (r 5 0.49, p ,
0.0001), with systemic vascular resistance (r 5 0.31, p 5
0.01), with mean arterial blood pressure (r 5 0.29, p 5
0.016), with MPAP (r 5 0.47, p , 0.0001), with PCWP
(r 5 0.32, p 5 0.009) and with right atrial pressure (r 5
0.38, p 5 0.0016) but not with CI (r 5 20.21, p 5 0.09)
nor heart rate (r 5 0.18, p 5 0.15). Norepinephrine plasma
levels were positively correlated with ET-1 plasma levels
(r 5 0.57, p 5 0.004).
Epinephrine plasma levels only correlated with PCWP
(r 5 0.41, p 5 0.0006) and with MPAP (r 5 0.34, p 5
0.005) but not with the other hemodynamic parameters.
Also, there was no significant correlation between epineph-
rine and ET-1 plasma levels. Epinephrine, however, corre-
lated with norepinephrine levels (r 5 0.62, p 5 0.023).
Plasma catecholamines remained stable or decreased
slightly after administration of LU135252.
Plasma levels of LU135252. Plasma levels of the selective
ETA receptor antagonist LU135252 increased dose depen-
dently after single oral administration of various dosages.
Peak plasma levels occurred between 120 and 180 min after
administration (at 180 min: 31 6 4 ng/ml after 1 mg, 430 6
40 after 10 mg, 1,006 6 103 ng/ml after 30 mg, 4,092 6
560 ng/ml after 100 mg and 14,266 6 1,221 ng/ml after
300 mg; ptrend , 0.0001) and remained elevated over 24 h
(ptrend , 0.0001).
Safety. Fourteen adverse events were recorded in the pa-
tients receiving LU135252 (Table 5): one patient developed
Figure 1. Correlations between baseline endothelin (ET)-1
plasma levels and hemodynamic parameters in patients with
chronic heart failure (n 5 91). Mean pulmonary artery
(MPAP, mm Hg; top) and pulmonary capillary wedge pressure
(PCWP, mm Hg; middle) correlated positively with ET-1 plasma
levels, while cardiac index (mlzmin21zm22; bottom) was inversely
associated with ET-1 levels.
Figure 2. Changes of cardiac index and systemic vascular resis-
tance 4 h after administration of different dosages of LU135252, a
selective ETA receptor antagonist. *p , 0.05; **p # 0.0002.
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hypotension after 30 mg of LU135252 and one patient
developed markedly elevated pulmonary artery pressure
(71/38 mm Hg, mean 51 mm Hg) pulmonary edema (after
10 mg). Four cases (5.3%) of mild to moderate headache
occurred. In two patients bilirubin levels increased (four-
fold and two-fold) without increases in liver transaminases
and alkaline phosphatase. One case of ventricular tachycar-
dia was classified as unlikely to be related to the study
medication. One patient had a decrease in platelet count
(from 3719000 to 1289000 ml21) 15 min before adminis-
tration of the study drug, which spontaneously normalized
4 h later (to 2559000 ml21). The same patient experienced
a headache and a decrease in activated partial prothrombin
time 240 min after the study drug, which also normalized
spontaneously. One case of neck pain, one case of high
glucose and one case of preexisting anemia were classified as
unrelated. All patients recovered without sequelae.
DISCUSSION
This study demonstrates that a single oral dose of the
selective ETA receptor antagonist LU135252 has marked
beneficial hemodynamic effects in patients with chronic
heart failure. Cardiac index increased, while systemic vas-
cular resistance decreased in a dose-dependent manner, as
did pulmonary vascular resistance. Importantly, these favor-
able effects occurred in the absence of neurohormonal
stimulation or increases of heart rate. The improvement in
hemodynamics was comparable with that observed with
nonselective ETA/B receptor antagonists but was accompa-
nied by a smaller increase in ET-1 plasma levels (23,24).
The results substantiate the concept that ET-1 importantly
contributes to increased peripheral resistance and to the
decrease in cardiac output in chronic heart failure.
Hemodynamic effects of selective ETA antagonism in
heart failure. Increased peripheral resistance is a key fea-
ture of CHF that further impairs cardiac performance.
Vasoconstriction is a consequence of the activation of
several neurohormonal systems, e.g., the sympathetic ner-
vous system (13,29) and the renin angiotensin system (18).
In line with this concept, ET-1 plasma levels are elevated in
heart failure patients and correlate with hemodynamic
severity (15,17,19,30,31). Also, in this large population of
patients with CHF, we found a close positive relation of
ET-1 plasma levels with systemic and pulmonary pressures
and resistances and an inverse relation to cardiac output. In
this study, LU135252 led to venous, pulmonary and arterial
vasodilation and caused a pronounced increase in cardiac
output. There were no signs of an activation of the sympa-
thetic nervous system after administration of LU135252.
Indeed, both plasma catecholamine levels and heart rate
remained stable in spite of the marked hemodynamic effects.
The hemodynamic effects of LU135252 as well as the
presence of the compound in plasma lasted for approxi-
mately 24 h. The dose dependency of the effects of
LU135252 on CI and pulmonary vascular resistance was
Figure 3. Changes of endothelin-1 plasma levels after administra-
tion of various dosages of the selective ETA receptor antagonist
LU135252. There was a dose-dependent increase in plasma ET-1
levels. *p , 0.003 vs. baseline.
Table 4. Mean Hemodynamic Baseline Values and Absolute Changes According to Treatment
Baseline
LU135252 Dose
ptrend1 mg 10 mg 30 mg 100 mg 300 mg
CI (l/min) 2.28 6 0.04 0.18 6 0.08 0.24 6 0.10 0.30 6 0.08* 0.44 6 0.10* 0.50 6 0.09* ,0.001
HR (beats/min) 73.2 6 1.5 23.3 6 2.0 0.1 6 1.9 21.5 6 1.7 22.0 6 1.2 20.2 6 1.5 0.55
MAP (mm Hg) 91.2 6 1.4 24.6 6 1.2* 24.5 6 1.4* 23.1 6 1.5* 25.0 6 1.5* 28.7 6 1.4* 0.09
SVR (dynzs21zcm25) 1,570 6 40 2169 6 35 2165 6 57* 2207 6 63* 2317 6 56* 2424 6 52* ,0.001
RAP (mm Hg) 7.3 6 0.4 20.9 6 0.5 21.2 6 0.3 21.4 6 0.4* 21.3 6 0.4* 21.1 6 0.6 0.81
MPAP (mm Hg) 30.1 6 1.2 23.0 6 1.0 25.1 6 1.1* 25.1 6 1.4* 26.0 6 0.8* 24.0 6 1.1* 0.47
PCWP (mm Hg) 19.0 6 0.7 22.8 6 1.1* 24.7 6 1.0* 24.2 6 0.7* 24.8 6 0.7* 23.1 6 0.9* 0.86
PVR (dynzs21zcm25) 204 6 16 212 6 11 225 6 12 224 6 17 249 6 10* 253 6 13* ,0.02
Values are means 6 SE and represent the average mean responses at 120, 180 and 240 min, adjusted for baseline levels.
*Significant change vs. baseline (Bonferroni-adjusted alpha-level of 0.01).
CI 5 cardiac index; HR 5 heart rate; MAP 5 mean systemic arterial pressure; MPAP 5 mean pulmonary artery pressure; PCWP 5 pulmonary capillary wedge pressure;
PVR 5 pulmonary vascular resistance; RAP 5 right atrial pressure; SVR 5 systemic vascular resistance.
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quite obvious; higher dosages were hemodynamically clearly
more effective than the lower dosages. In contrast to
hypertension, dose selection is difficult in CHF as there is
no documented surrogate end point for morbidity and
mortality. Although the hemodynamic effects of LU135252
may be favorable, not all drugs with such effects improved
prognosis in CHF (e.g., milrinone, flosequinan) (32–34).
The fact that ET correlates with prognosis (15–17), how-
ever, strongly suggests that blockade of the system may be
clinically important for morbidity and mortality.
Endothelin plasma levels in heart failure. Plasma levels
of ET-1 and its precursor, big ET-1, are strong indepen-
dent predictors of death (16,35). Thus, ET antagonists are
of great clinical interest as mortality remains high in patients
with CHF in spite of currently available drugs.
Endothelin-1 exerts its vasoconstrictive effects through
activation of ETA and ETB receptors on vascular smooth
muscle cells. The ETA receptor also mediates proliferation
of vascular smooth muscle cells (9). In contrast, ETB
receptors on endothelial cells mediate the release of vasodi-
lating and antiproliferative NO and prostaglandins (10–12)
and are involved in the clearance of ET-1 (22–25). Indeed,
selective ETB antagonism exerts unfavorable hemodynamic
effects (36,37). Therefore, there is particular interest in
selective ETA receptor antagonists as therapeutic agents in
chronic heart failure. As in previous studies with other
ET-1 receptor antagonists, ET-1 plasma levels increased
significantly after administration of the selective ETA re-
ceptor antagonist LU135252, presumably due to displace-
ment of ET-1 from its receptors. However, changes in
plasma ET-1 were clearly smaller than those observed after
administration of bosentan, a nonselective ETA/B receptor
antagonist although the selective ETA receptor antagonist
LU135252 was at least as hemodynamically potent as the
combined ETA/B receptor antagonist, both on the arterial
and venous side of the circulation (4,19,20,38,39). Thus, the
present findings suggest that selective ETA blockade, which
does not interfere with ETB receptors, does not impair
clearance of ET-1 from the human circulation (22–25).
This can have clinical relevance as elevated ET-1 plasma
levels in chronic heart failure are, in part, due to down-
regulation of lung ETB receptors with subsequent reduced
clearance of ET-1 (40,41). Further, the risk of adverse
events after drug withdrawal (e.g., rebound vasoconstric-
tion) seems to be much lower.
Safety and tolerability. The ETA receptor antagonist
LU135252 was generally well tolerated. In this study, there
was one episode of pulmonary edema in a patient with
markedly elevated pulmonary artery pressure and one epi-
sode of hypotension. In a previous study on the hemody-
namic effects of another selective ETA receptor antagonist,
BQ-123, an episode of syncope and bradycardia was de-
scribed, which also occurred in a patient with markedly
elevated pulmonary artery pressure (42). Special care may,
therefore, be required when starting endothelin antagonists
in patients with severe chronic heart failure, as is the case
with angiotensin-converting enzyme inhibitors or beta-
blockers (43).
Study limitations. This study has several limitations. First,
since only short-term hemodynamic and neurohormonal
effects were studied, valid conclusions concerning long-term
safety and efficacy cannot be drawn yet. Second, for safety
reasons, all drugs with impact on hemodynamics were
halted before administration of the study drug. Therefore,
interactions with other drugs may be more important in
daily practice than under the conditions of this study. Third,
the study was not placebo-controlled but, rather, compared
a wide range of dosages of an active drug (i.e., LU135252).
However, in previous studies, placebo did not exert any
hemodynamic effects in patients with heart failure under the
experimental conditions utilized in these patients (19,20).
Also, the striking dose-dependency of the effects of
LU135252 on CI and pulmonary vascular resistance
strongly argues for a very specific mode of action. To
address these limitations, further studies are, therefore,
under way.
Table 5. Adverse Events
Adverse Event
Observed
Frequency
Relation to
Study
Medication
Headache 4.2% (n 5 4) probable (2), possible (1), unrelated (1)
Increased bilirubin 2.1% (n 5 2) possible
Hypotension 1.1% (n 5 1) possible
Pulmonary edema 1.1% (n 5 1) unlikely
Ventricular tachycardia 1.1% (n 5 1) unlikely
Neck pain 1.1% (n 5 1) unrelated
Hyperglycemia 1.1% (n 5 1) unrelated
Preexisting anemia 1.1% (n 5 1) unrelated
Decrease in activated partial
prothrombin time
1.1% (n 5 1) possible
Decrease in platelet count 1.1% (n 5 1) unrelated
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Summary and conclusions. In summary, this study for the
first time shows in a large patient population that the
selective ETA receptor antagonist LU135252 improves
hemodynamics in patients with chronic heart failure. Ad-
ministration of LU135252 was not accompanied by neuro-
hormonal stimulation and caused smaller increases in ET-1
plasma levels than the previously reported nonselective
ETA/B receptor antagonists. The results suggest that ETA
receptors are of primary importance for the hemodynamic
abnormalities in CHF and support the concept that ETB
receptors play an important role in clearance of ET-1 from
the human circulation.
Acknowledgments
The authors would like to acknowledge the participating
centers: Allgemeines Krankenhaus, Vienna, Austria (R.
Pacher); Department of Cardiology, Gentofte University
Hospital, Hellerup, Denmark (C. Torp-Pedersen);
Kerckhoff-Klinik GmbH, Bad Nauheim, Germany (V.
Mitrovic); Herz-und Kreislaufzentrum-Abteilung Kardi-
ologie, Dresden, Germany (M. R. Schulze); Institute of
Cardiology, Silesian Med. Academy, Katowice, Poland (M.
Tendera); Instytut Kardiologii CMUJ, Krakow, Poland (A.
Dziatkowiak); Clinic of Cardiology, Clinical Hospital,
Lodz, Poland (M. J. Kosmider); Klinika Kardiologii,
Szczecin, Poland (Z. Kornacewicz-Jach); Clinic of Cardi-
ology, Warsaw, Poland (W. Ruzyllo); Clinic of Cardiology,
Silesian Medical Academy, Zabrze, Poland (L. Polonski);
Cardiology, University Hospital, Zurich, Switzerland (T. F.
Lu¨scher). The authors thank Sidney Shaw (Berne, Switzer-
land) for determination of ET-1 plasma levels. The study
was organized, in part, by InterCorNet (Clinical Research
Center, Zurich, Switzerland).
Reprint requests and correspondence: Dr. Thomas F. Lu¨scher,
Cardiology, University Hospital, CH-8091, Zu¨rich, Switzerland.
E-mail: cardiotfl@compuserve.com.
REFERENCES
1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasocon-
strictor peptide produced by vascular endothelial cells. Nature 1988;
332:411–5.
2. Lu¨scher TF, Vanhoutte PM. The Endothelium: Modulator of Car-
diovascular Function. Boca Raton: CRC, 1990.
3. Haynes WG, Webb DJ. Contribution of endogenous generation of
endothelin-1 to basal vascular tone. Lancet 1994;344:852–4.
4. Seo B, Oemar BS, Siebenmann R, von Segesser L, Lu¨scher TF. Both
ETA and ETB receptors mediate contraction to endothelin-1 in
human blood vessels. Circulation 1994;89:1203–8.
5. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA
encoding a nonisopeptide-selective subtype of the endothelin receptor.
Nature 1990;348:732–5.
6. Sumner MJ, Cannon TR, Mundin JW, White DG, Watts IS.
Endothelin ETA and ETB receptors mediate vascular smooth muscle
cell contraction. Br J Pharmacol 1992;107:858–60.
7. Seo B, Lu¨scher TF. ETA and ETB receptors mediate contraction to
endothelin-1 in renal artery of aging SHR. Effects of FR139317 and
bosentan. Hypertension 1995;25:501–6.
8. Ito H, Hirata Y, Hiroe M, et al. ET-1 induces hypertrophy with
enhanced expression of muscle specific genes in cultured neonatal rat
cardiomyocytes. Circ Res 1991;69:209–15.
9. Yang Z, Krasnici N, Lu¨scher TF. Endothelin-1 potentiates smooth
muscle cell growth to PDGF: role of ETA and ETB receptor
blockade. Circulation 1999;100:5–8.
10. Haynes WG, Webb DJ. Endothelium-dependent modulation of
responses to endothelin-1 in human veins. Cli Sci (Colch) 1993;84:
427–33.
11. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in
the relaxation of arterial smooth muscle by acetylcholine. Nature
1980;288:373–6.
12. Garg UC, Hassid A. Nitric oxide-generating vasodilators and
8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and
proliferation of cultured rat vascular smooth muscle cells. J Clin Invest
1989;83:1774–7.
13. Leimbach WJ, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark
AL. Direct evidence from intraneural recordings for increased central
sympathetic outflow in patients with heart failure. Circulation 1986;
73:913–9.
14. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity
of the sympathetic nervous system and renin-angiotensin system
assessed by plasma hormone levels and their relation to hemodynamic
abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659–
66.
15. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated
endothelin-1 in heart failure and loss of normal response to postural
change. Circulation 1992;85:510–7.
16. Pacher R, Stanek B, Hu¨lsmann M, et al. Prognostic impact of big
endothelin-1 plasma concentrations compared with invasive hemody-
namic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:
633–41.
17. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma
endothelin in chronic heart failure. Circulation 1992;85:1374–9.
18. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita
Y. Inhibition of myocardial endothelin pathway improves long-term
survival in heart failure. Nature 1996;384:353–5.
19. Kiowski W, Su¨tsch G, Hunziker P, et al. Evidence for endothelin-1-
mediated vasoconstriction in severe chronic heart failure. Lancet
1995;346:732–6.
20. Su¨tsch G, Kiowski W, Yan X-W, et al. Short-term oral endothelin-
receptor antagonist therapy in conventionally treated patients with
symptomatic severe chronic heart failure. Circulation 1998;98:2262–8.
21. Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the
L-arginine-nitric oxide metabolic pathway in patients with congestive
heart failure. Circulation 1999;99:2113–7.
22. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M.
Clearance of circulating endothelin-1 by ETB receptors in rats.
Biochem Biophys Res Commun 1994;1999:1461–5.
23. Ozaki S, Ohwaki K, Ihara M, Fukuroda T, Ishikawa K, Yano M.
ETB-mediated regulation of extracellular levels of endothelin-1 in
cultured human endothelial cells. Biochem Biophys Res Commun
1995;209:483–9.
24. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating
endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl
Physiol 1996;81:1510–5.
25. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary
circulation is an important site for both clearance and production of
endothelin-1. Circulation 1996;94:1578–84.
26. Smedes F, Kraak JC, Poppe H. Simple and fast solvent extraction
system for selective and quantitative isolation of adrenaline, noradren-
aline and dopamine from plasma and urine. J Chromatogr 1982;231:
25–39.
27. Sorensen SS. Radio-immunoassay of endothelin in human plasma.
Scand J Clin Lab Invest 1991;51:615–23.
28. Hjemdahl P. Catecholamine measurements by high-performance liq-
uid chromatography. Am J Physiol 1984;247:E13–20.
29. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a
guide to prognosis in patients with chronic congestive heart failure.
N Engl J Med 1984;311:819–23.
30. Margulies KB, Hildebrand FJ, Lerman A, Perrella MA, Burnett
JJ. Increased endothelin in experimental heart failure. Circulation
1990;82:2226–30.
31. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma
endothelin correlates with the extent of pulmonary hypertension in
1751JACC Vol. 35, No. 7, 2000 Spieker et al.
June 2000:1745–52 ETA Antagonism in Heart Failure
patients with chronic congestive heart failure. Circulation 1992;85:
504–9.
32. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on
mortality in severe chronic heart failure. The PROMISE Study
Research Group. N Engl J Med 1991;325:1468–75.
33. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be
achieved by adding flosequinan to patients with congestive heart failure
who remain symptomatic on diuretic, digoxin and an angiotensin-
converting enzyme inhibitor? Results of the flosequinan-ACE inhib-
itor trial (FACET). Circulation 1993;88:492–501.
34. Packer M, Narahara KA, Elkayam U, et al. Double-blind, placebo-
controlled study of the efficacy of flosequinan in patients with chronic
heart failure. Principal Investigators of the REFLECT Study. J Am
Coll Cardiol 1993;22:65–72.
35. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma
endothelin determination as a prognostic indicator of one-year mor-
tality after acute myocardial infarction (see comments). Circulation
1994;89:1573–9.
36. Wada A, Tsutamoto T, Fukai D, et al. Comparison of the effects of
selective endothelin ETA and ETB receptor antagonists in congestive
heart failure. J Am Coll Cardiol 1997;30:1385–92.
37. Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb
DJ. Systemic blockade of the endothelin-B receptor increases peripheral
vascular resistance in healthy men. Hypertension 1999;33:581–5.
38. Wenzel RR, Fleisch M, Shaw S, et al. Hemodynamic and coronary
effects of the endothelin antagonist, bosentan, in patients with coro-
nary artery disease. Circulation 1998;98:2235–40.
39. Cowburn PJ, Cleland JG, McArthur JD, et al. Endothelin B receptors
are functionally important in mediating vasoconstriction in the sys-
temic circulation in patients with left ventricular systolic dysfunction.
J Am Coll Cardiol 1999;33:932–8.
40. Kobayshi T, Miyauchi T, Sakai S, et al. Down-regulation of ET(B)
receptor, but not ET(A) receptor, in congestive lung secondary to
heart failure. Are marked increases in circulating endothelin-1 partly
attributable to decreases in lung ET(B) receptor-mediated clearance of
endothelin-1? Life Sci 1998;62:185–93.
41. Dupuis J, Rouleau JL, Cernacek P. Reduced pulmonary clearance of
endothelin-1 contributes to the increase of circulating levels in heart
failure secondary to myocardial infarction. Circulation 1998;98:
1684–7.
42. Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, McMurray
JJ, Dargie HJ. Short-term haemodynamic effects of BQ-123, a
selective endothelin ET(A)-receptor antagonist, in chronic heart
failure (letter). Lancet 1998;352:201–2.
43. Cleland JG, Dargie HJ, McAlpine H, et al. Severe hypotension after
first dose of enalapril in heart failure. Br Med J (Clin Res Ed)
1985;291:1309–12.
1752 Spieker et al. JACC Vol. 35, No. 7, 2000
ETA Antagonism in Heart Failure June 2000:1745–52
